
ONC-392
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
Loading color scheme
From novel biology to clinical stage products.
Best-in-class and first-in-class immunotherapy products targeting cancer evasion of adaptive and innate immunity.
Our team brings success from biotech pharma, and academia to OncoC4.
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
Targeting cancer cells through chimeric antigen receptors T cells (ONC-782), bi-specific antibodies (ONC-783) and antibody-drug conjugates (ONC-784).
OncoC4 has a pipeline of best-in-class and first-in-class immunotherapy products that are moving through preclinical testing.
Developing unique drugs that uncouple therapeutic effects and immunotherapy-related adverse effects.
Scientific discoveries drive explosive immunotherapy.
ROCKVILLE, Md., USA, Sept 28, 2023 (GLOBE NEWSWIRE) — OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today announced the appointment of Abid Ansari as Chief Financial Officer (CFO), effective immediately. Abid brings over 20 years of expertise in financial strategy and business development for public and…
Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s strategic collaboration initiated in March 2023 with the aim to evaluate BNT316/ONC-392 in various solid tumor indications The randomized Phase 3 trial is expected to enroll approximately 600 patients with…
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC) Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year’s ASCO Annual…